BeiGene (NASDAQ:BGNE) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BeiGene (NASDAQ:BGNE) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the stock.

A number of other research firms also recently weighed in on BGNE. TD Cowen boosted their target price on shares of BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Morgan Stanley reissued an “overweight” rating and set a $300.00 price objective on shares of BeiGene in a research note on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. raised their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.69.

BeiGene Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. BeiGene has a one year low of $126.97 and a one year high of $248.16. The company’s 50 day moving average price is $194.32 and its 200 day moving average price is $188.98. The company has a market capitalization of $18.03 billion, a price-to-earnings ratio of -22.42 and a beta of 0.57.

BeiGene (NASDAQ:BGNE) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same quarter in the prior year, the company posted $2.01 earnings per share. The firm’s revenue was up 28.2% compared to the same quarter last year. As a group, equities research analysts forecast that BeiGene will post -5.64 earnings per share for the current fiscal year.

Insider Activity

In other BeiGene news, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the sale, the director now directly owns 791,493 shares of the company’s stock, valued at $148,222,894.11. The trade was a 56.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Xiaodong Wang sold 40,468 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,119,245 shares of company stock valued at $209,700,084. 7.43% of the stock is currently owned by insiders.

Institutional Trading of BeiGene

A number of large investors have recently modified their holdings of the company. Blue Trust Inc. increased its holdings in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after purchasing an additional 75 shares during the period. Truist Financial Corp grew its position in shares of BeiGene by 10.1% during the 2nd quarter. Truist Financial Corp now owns 1,521 shares of the company’s stock worth $217,000 after buying an additional 140 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene during the third quarter valued at $36,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of BeiGene by 0.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 97,895 shares of the company’s stock valued at $21,978,000 after acquiring an additional 266 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in BeiGene in the third quarter worth about $67,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.